Research programme: viral vaccines - Okairos

Drug Profile

Research programme: viral vaccines - Okairos

Latest Information Update: 02 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Okairos
  • Developer Okairos; ReiThera
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza virus infections; Marburg virus disease
  • Discontinued Cytomegalovirus infections; Human papillomavirus infections

Most Recent Events

  • 29 May 2013 Okairos has been acquired by GlaxoSmithKline
  • 27 Feb 2013 The Okairos viral vaccines programme is still in Preclinical trials for Marburg virus disease and influenza virus infections (prevention) in Italy
  • 30 Sep 2011 Discontinued - Preclinical for Cytomegalovirus infections (prevention) in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top